Beijing LuHe Hospital, Capital Medical University
Beijing, Beijing Municipality, China
NCT Number: NCT06236841
This is a phase I, randomised, double-blind placebo-controlled, 3-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of XH-S004 in healthy volunteers.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusive criteria:
Exclusive criteria:
XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days
Other names: FXS7553
Matching placebo tablets will be administered orally as per assigned treatment regimen on schedualed days
Time frame: Approximately 1~2 weeks.
The incidence and severity of adverse events (AEs) , serious AEs and abnormalities on laboratory tests.
Time frame: Approximately 2 months.
The incidence and severity of adverse events (AEs) , serious AEs and abnormalities on laboratory tests.
S-INFINITY Pharmaceuticals Co., Ltd
Industry
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S004 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06902571
Healthy Adults
Hong Kong, Hung Hom
View Trial DetailsNCT06635161
Healthy Adults
Hong Kong, Hung Hom, Kowloon
View Trial DetailsNCT07284173
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis
Beijing, Beijing Municipality, China
View Trial DetailsNCT07809412
Attention, Cognitive Training
Beykoz, Istanbul, Turkey (Türkiye)
View Trial Details